IL-15 activates mTOR and primes stress-activated gene expression leading to prolonged antitumor capacity of NK cells.

Treatment of hematological malignancies by adoptive transfer of activated natural killer (NK) cells is limited by poor postinfusion persistence. We compared the ability of interleukin-2 (IL-2) and IL-15 to sustain human NK-cell functions following cytokine withdrawal to model postinfusion performance. In contrast to IL-2, IL-15 mediated stronger signaling through the IL-2/15 receptor complex and provided cell function advantages. Genome-wide analysis of cytosolic and polysome-associated messenger RNA (mRNA) revealed not only cytokine-dependent differential mRNA levels and translation during cytokine activation but also that most gene expression differences were primed by IL-15 and only manifested after cytokine withdrawal. IL-15 augmented mammalian target of rapamycin (mTOR) signaling, which correlated with increased expression of genes related to cell metabolism and respiration. Consistently, mTOR inhibition abrogated IL-15-induced cell function advantages. Moreover, mTOR-independent STAT-5 signaling contributed to improved NK-cell function during cytokine activation but not following cytokine withdrawal. The superior performance of IL-15-stimulated NK cells was also observed using a clinically applicable protocol for NK-cell expansion in vitro and in vivo. Finally, expression of IL-15 correlated with cytolytic immune functions in patients with B-cell lymphoma and favorable clinical outcome. These findings highlight the importance of mTOR-regulated metabolic processes for immune cell functions and argue for implementation of IL-15 in adoptive NK-cell cancer therapy.

[1]  J. Pelletier,et al.  nanoCAGE reveals 5′ UTR features that define specific modes of translation of functionally related MTOR-sensitive mRNAs , 2016, Genome research.

[2]  S. Biswas.  Metabolic Reprogramming of Immune Cells in Cancer Progression. , 2015, Immunity.

[3]  R. Schreiber,et al.  Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression , 2015, Cell.

[4]  Steven L Salzberg,et al.  HISAT: a fast spliced aligner with low memory requirements , 2015, Nature Methods.

[5]  M. Cooper,et al.  Activation-Specific Metabolic Requirements for NK Cell IFN-γ Production , 2015, The Journal of Immunology.

[6]  M. Nishimura,et al.  Promoting thiol expression increases the durability of antitumor T-cell functions. , 2014, Cancer research.

[7]  D. Campana,et al.  Autonomous growth and increased cytotoxicity of natural killer cells expressing membrane-bound interleukin-15. , 2014, Blood.

[8]  J. Wagner,et al.  Expansion and homing of adoptively transferred human natural killer cells in immunodeficient mice varies with product preparation and in vivo cytokine administration: implications for clinical therapy. , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[9]  B. Seliger,et al.  Inhibition of Tumor-Derived Prostaglandin-E2 Blocks the Induction of Myeloid-Derived Suppressor Cells and Recovers Natural Killer Cell Activity , 2014, Clinical Cancer Research.

[10]  Stephen N. Jones,et al.  Oxygen sufficiency controls TOP mRNA translation via the TSC-Rheb-mTOR pathway in a 4E-BP-independent manner. , 2014, Journal of molecular cell biology.

[11]  P. Kafasla,et al.  Post-transcriptional coordination of immunological responses by RNA-binding proteins , 2014, Nature Immunology.

[12]  N. Sonenberg,et al.  Translational control of immune responses: from transcripts to translatomes , 2014, Nature Immunology.

[13]  T. Alain,et al.  Polysome Fractionation and Analysis of Mammalian Translatomes on a Genome-wide Scale , 2014, Journal of visualized experiments : JoVE.

[14]  C. Collins,et al.  IL-15 maintains T-cell survival via S-nitrosylation-mediated inhibition of caspase-3 , 2014, Cell Death and Differentiation.

[15]  Jeffrey S. Miller.  Therapeutic applications: natural killer cells in the clinic. , 2013, Hematology. American Society of Hematology. Education Program.

[16]  D. Lauffenburger,et al.  Qualitatively Different T Cell Phenotypic Responses to IL-2 versus IL-15 Are Unified by Identical Dependences on Receptor Signal Strength and Duration , 2013, The Journal of Immunology.

[17]  N. Sonenberg,et al.  mTORC1 controls mitochondrial activity and biogenesis through 4E-BP-dependent translational regulation. , 2013, Cell metabolism.

[18]  Åsa K. Björklund,et al.  Smart-seq2 for sensitive full-length transcriptome profiling in single cells , 2013, Nature Methods.

[19]  N. Sonenberg,et al.  Distinct Translational Control in CD4+ T Cell Subsets , 2013, PLoS genetics.

[20]  H. Harizi.  Reciprocal crosstalk between dendritic cells and natural killer cells under the effects of PGE2 in immunity and immunopathology , 2013, Cellular and Molecular Immunology.

[21]  Masahiro Morita,et al.  Distinct perturbation of the translatome by the antidiabetic drug metformin , 2012, Proceedings of the National Academy of Sciences.

[22]  D. Sabatini,et al.  A unifying model for mTORC1-mediated regulation of mRNA translation , 2012, Nature.

[23]  Nicholas T. Ingolia,et al.  The translational landscape of mTOR signalling steers cancer initiation and metastasis , 2012, Nature.

[24]  T. Malek,et al.  The Basis of Distinctive IL-2– and IL-15–Dependent Signaling: Weak CD122-Dependent Signaling Favors CD8+ T Central-Memory Cell Survival but Not T Effector-Memory Cell Development , 2011, The Journal of Immunology.

[25]  Jian-xin Lin,et al.  IL-2 family cytokines: new insights into the complex roles of IL-2 as a broad regulator of T helper cell differentiation. , 2011, Current opinion in immunology.

[26]  G. Suck,et al.  Interleukin-15 supports generation of highly potent clinical-grade natural killer cells in long-term cultures for targeting hematological malignancies. , 2011, Experimental hematology.

[27]  S. Mehrotra,et al.  T cells expanded in presence of IL-15 exhibit increased antioxidant capacity and innate effector molecules. , 2011, Cytokine.

[28]  M. Berg,et al.  Bortezomib Treatment to Potentiate the Anti-tumor Immunity of Ex-vivo Expanded Adoptively Infused Autologous Natural Killer Cells , 2011, Journal of Cancer.

[29]  Robert Nadon,et al.  Anota: Analysis of Differential Translation in Genome-wide Studies , 2011, Bioinform..

[30]  T. Waldmann,et al.  Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaques. , 2011, Blood.

[31]  J. Sarkaria,et al.  Combination of Temsirolimus (CCI-779) with Chemoradiation in Newly Diagnosed Glioblastoma Multiforme (GBM) (NCCTG trial N027D) Is Associated with Increased Infectious Risks , 2010, Clinical Cancer Research.

[32]  B. Lindgren,et al.  Allogeneic natural killer cells for refractory lymphoma , 2010, Cancer Immunology, Immunotherapy.

[33]  H. Kiyono,et al.  IL-15 triggers an antiapoptotic pathway in human intraepithelial lymphocytes that is a potential new target in celiac disease-associated inflammation and lymphomagenesis. , 2010, The Journal of clinical investigation.

[34]  Jeong-Ho Kim,et al.  Signal Transducer and Activator of Transcription 3 (STAT3) Mediates Amino Acid Inhibition of Insulin Signaling through Serine 727 Phosphorylation* , 2009, The Journal of Biological Chemistry.

[35]  S. Riddell,et al.  Safety and immunologic effects of IL-15 administration in nonhuman primates. , 2009, Blood.

[36]  Peter J. Woolf,et al.  GAGE: generally applicable gene set enrichment for pathway analysis , 2009, BMC Bioinformatics.

[37]  L. Staudt,et al.  Stromal gene signatures in large-B-cell lymphomas. , 2008, The New England journal of medicine.

[38]  K. Stuhlmeier,et al.  The TSC-mTOR signaling pathway regulates the innate inflammatory response. , 2008, Immunity.

[39]  L. Moretta,et al.  Molecular analysis of the methylprednisolone-mediated inhibition of NK-cell function: evidence for different susceptibility of IL-2- versus IL-15-activated NK cells. , 2007, Blood.

[40]  T. Waldmann.  The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design , 2006, Nature Reviews Immunology.

[41]  C. Le,et al.  Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. , 2005, Blood.

[42]  Jun Yan.  Survival Analysis: Techniques for Censored and Truncated Data , 2004 .

[43]  Richard Simon,et al.  A random variance model for detection of differential gene expression in small microarray experiments , 2003, Bioinform..

[44]  S. Love,et al.  Survival Analysis Part III: Multivariate data analysis – choosing a model and assessing its adequacy and fit , 2003, British Journal of Cancer.

[45]  Katia Perruccio,et al.  Effectiveness of Donor Natural Killer Cell Alloreactivity in Mismatched Hematopoietic Transplants , 2002, Science.

[46]  C. Feighery,et al.  Selective Expansion and Partial Activation of Human NK Cells and NK Receptor-Positive T Cells by IL-2 and IL-151 , 2001, The Journal of Immunology.

[47]  P. Morrissey,et al.  Reversible Defects in Natural Killer and Memory Cd8 T Cell Lineages in Interleukin 15–Deficient Mice , 2000, The Journal of experimental medicine.

[48]  H. Naora,et al.  Interleukin-15 is a potent survival factor in the prevention of spontaneous but not CD95-induced apoptosis in CD4 and CD8 T lymphocytes of HIV-infected individuals. Correlation with its ability to increase BCL-2 expression , 1999, Cell Death and Differentiation.

[49]  T. Dassopoulos,et al.  IL-15 receptor maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation. , 1998, Immunity.

[50]  J. Sprent,et al.  Potent and selective stimulation of memory-phenotype CD8+ T cells in vivo by IL-15. , 1998, Immunity.

[51]  T. Mak,et al.  Abnormal Development of Intestinal Intraepithelial Lymphocytes and Peripheral Natural Killer Cells in Mice Lacking the IL-2 Receptor β Chain , 1997, The Journal of experimental medicine.

[52]  A. Fischer,et al.  Lymphoid development in mice with a targeted deletion of the interleukin 2 receptor gamma chain. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[53]  T. Waldmann,et al.  Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  M. Caligiuri,et al.  Interleukin 15: biology and relevance to human disease. , 2001, Blood.

[55]  J. Avruch,et al.  Serine phosphorylation and maximal activation of STAT3 during CNTF signaling is mediated by the rapamycin target mTOR , 2000, Current Biology.